Monique Patricio Singulani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Monique Patricio Singulani has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Orestes Vicente Forlenza
Universidade de São Paulo, Brazil
4 shared publications - Antonio Hernandes Chaves-Neto
Department of Basic Sciences, Araçatuba School of Dentistry, São Paulo State University (UNESP), Araçatuba 16015-050, SP, Brazil
3 shared publications - Leandro Figueiredo Santos
Universidade Paulista (UNIP)
3 shared publications - Luiz Roberto G. Britto
Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
3 shared publications - Rita Cássia Menegati Dornelles
Programa de Pós-Graduação Multicêntrico em Ciências Fisiológicas, SBFis, São Paulo State University (UNESP), Araçatuba, São Paulo, Brazil; Department of Basic Sciences, School of Dentistry, São Paulo State University (UNESP), Araçatuba, São Paulo, Brazil
3 shared publications - Ana Flavia Fernandes Ferreira
Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e107377
Subtherapeutic dose lithium treatment induces behavioral and neuropathological changes in 3xTg‐AD Alzheimer's mice
Background: Alzheimer's disease (AD) is the most common cause of dementia and a global health challenge. The efficacy of lithium salts in stabilizing moods and neuroprotective effects has stimulated research into their use in neurodegenerative diseases. Method: We tested lithium carbonate treatment (1.0g Li 2 CO 3 /kg of chow; 12‐weeks) in 3xTg‐AD and age‐matched Wild‐Type male mice of 12‐month‐old. (CEUA/PROCESS: 1605/2020; 4127240122). Two behavioral test batteries were performed: (1) open‐field test (OFT), novel‐object recognition test (NORT), elevated zero‐maze test (EZMT), and Rotarod test; (2) tail‐suspension test (TST), forced‐swim test (FST), and sucrose preference test (SPT). Immunohistochemistry method was performed to analyze amyloid‐β (Aβ) accumulation (6E10), phosphorylated tau ( p ‐TaupSer199/202), and neuronal viability (neuronal nuclei; NeuN) in areas of the brain. Statistical analysis: two‐way ANOVA followed by Bonferroni post‐hoc test and unpaired t‐test; statistically significant p (1, 28) =8.37; p (1, 28) =7.99; p (1, 28) =37.15; p (1, 28) =19,44; p (1, 28) =11.70; p (1, 28) =7.96; p (1, 24) =17,86; p p (1, 20) =417,90; p (1, 20) =417,74; p (1, 20) =1073,00; p (1, 22) =420,00; p (1, 27) =845,20; p (1, 27) =117,7; p (1, 27) =64,89; p (1, 27) =76,46; p (1, 27) =; p (1, 28) =8,61; p (1, 27) =70,54; p (1, 27) =75,35; p (1, 26) =38,67; p (1, 27) =72,77; p <0,0001]). Conclusion: The chronic lithium treatment significantly attenuates the pathological progression of AD, suggesting it as a potential therapeutic drug target for modifying AD. The study was funding by: São Paulo Research Foundation (FAPESP; 2021/06378‐1).
- 24 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S1) , e107377
Open AccessSubtherapeutic dose lithium treatment induces behavioral and neuropathological changes in 3xTg‐AD Alzheimer's mice
Background: Alzheimer's disease (AD) is the most common cause of dementia and a global health challenge. The efficacy of lithium salts in stabilizing moods and neuroprotective effects has stimulated research into their use in neurodegenerative diseases. Method: We tested lithium carbonate treatment (1.0g Li 2 CO 3 /kg of chow; 12‐weeks) in 3xTg‐AD and age‐matched Wild‐Type male mice of 12‐month‐old. (CEUA/PROCESS: 1605/2020; 4127240122). Two behavioral test batteries were performed: (1) open‐field test (OFT), novel‐object recognition test (NORT), elevated zero‐maze test (EZMT), and Rotarod test; (2) tail‐suspension test (TST), forced‐swim test (FST), and sucrose preference test (SPT). Immunohistochemistry method was performed to analyze amyloid‐β (Aβ) accumulation (6E10), phosphorylated tau ( p ‐TaupSer199/202), and neuronal viability (neuronal nuclei; NeuN) in areas of the brain. Statistical analysis: two‐way ANOVA followed by Bonferroni post‐hoc test and unpaired t‐test; statistically significant p (1, 28) =8.37; p (1, 28) =7.99; p (1, 28) =37.15; p (1, 28) =19,44; p (1, 28) =11.70; p (1, 28) =7.96; p (1, 24) =17,86; p p (1, 20) =417,90; p (1, 20) =417,74; p (1, 20) =1073,00; p (1, 22) =420,00; p (1, 27) =845,20; p (1, 27) =117,7; p (1, 27) =64,89; p (1, 27) =76,46; p (1, 27) =; p (1, 28) =8,61; p (1, 27) =70,54; p (1, 27) =75,35; p (1, 26) =38,67; p (1, 27) =72,77; p <0,0001]). Conclusion: The chronic lithium treatment significantly attenuates the pathological progression of AD, suggesting it as a potential therapeutic drug target for modifying AD. The study was funding by: São Paulo Research Foundation (FAPESP; 2021/06378‐1).
- Open Access
- 5 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 532
An Overview of the Effects of Lithium on Alzheimer’s Disease: A Historical Perspective
Lithium was introduced into psychiatric practice in the late nineteenth century and has since become a standard treatment for severe psychiatric disorders, particularly those characterized by psychotic agitation. It remains the most effective agent for managing acute mania and preventing relapses in bipolar disorder. Despite potential adverse effects, lithium’s use should be carefully considered relative to other treatment options, as these alternatives may present distinct safety and tolerability profiles. The World Health Organization classifies lithium salts as ‘essential’ medications for inclusion in global healthcare systems. Over the past two decades, the growing recognition of lithium’s efficacy—extending beyond mood stabilization to include reducing suicide risk and inducing neuroprotection—has led to its incorporation into clinical practice guidelines. Current research, particularly from translational models, suggests that lithium’s pleiotropic effects benefit not only mental and brain health but also other organs and systems. This supports its potential as a therapeutic candidate for neurological conditions, particularly those associated with neurodegenerative processes. This article will discuss the historical background, discovery, and early experimentation of lithium in psychiatry. We will also review its mechanisms of action and discuss its potential in the treatment and prevention of neurodegenerative disorders, focusing on Alzheimer’s disease.
- 5 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 532
Open AccessAn Overview of the Effects of Lithium on Alzheimer’s Disease: A Historical Perspective
Lithium was introduced into psychiatric practice in the late nineteenth century and has since become a standard treatment for severe psychiatric disorders, particularly those characterized by psychotic agitation. It remains the most effective agent for managing acute mania and preventing relapses in bipolar disorder. Despite potential adverse effects, lithium’s use should be carefully considered relative to other treatment options, as these alternatives may present distinct safety and tolerability profiles. The World Health Organization classifies lithium salts as ‘essential’ medications for inclusion in global healthcare systems. Over the past two decades, the growing recognition of lithium’s efficacy—extending beyond mood stabilization to include reducing suicide risk and inducing neuroprotection—has led to its incorporation into clinical practice guidelines. Current research, particularly from translational models, suggests that lithium’s pleiotropic effects benefit not only mental and brain health but also other organs and systems. This supports its potential as a therapeutic candidate for neurological conditions, particularly those associated with neurodegenerative processes. This article will discuss the historical background, discovery, and early experimentation of lithium in psychiatry. We will also review its mechanisms of action and discuss its potential in the treatment and prevention of neurodegenerative disorders, focusing on Alzheimer’s disease.
- 3 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 258-267
Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process
Background: Individuals with Down syndrome (DS) generally show neuropathological features of Alzheimer disease (AD). The trisomy of chromosome 21 causes an imbalance of antioxidant systems, which can be linked to AD pathophysiology. Objective: Verify the difference between the activity of antioxidant enzymes and products of the oxidation process in peripheral blood in non-trisomic (NT) and trisomic (DS) adults and elders and respective associations with cognitive impairment. Methods: A total of 120 subjects were included in this study. Sociodemographic and clinical information were collected as per protocol for participants in DS and NT groups. The cognitive state of the DS participants was established according to the Brazilian version of the Cambridge Examination for Mental Disorders of Older People with Down's syndrome and Others with Intellectual Disabilities (CAMDEX-DS). The CAMDEX interview was used for this purpose for participants in the NT group. Plasma samples were collected to evaluate protein carbonyl content, superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), malondialdehyde (MDA), and 4-hydroxy-2-nonenal (HNE). Results: We found increased levels of SOD and CAT activity in the DS group. When the groups were stratified by cognitive decline, elevated levels of SOD and CAT activity were found both in DS groups with and without decline. The activity of GPx was similar between the groups, as well as MDA and HNE. Conclusion: The results suggest that alterations of the antioxidative processes can be implicated in the onset of neurodegeneration observed in individuals with DS.
- 3 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 258-267
Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process
Background: Individuals with Down syndrome (DS) generally show neuropathological features of Alzheimer disease (AD). The trisomy of chromosome 21 causes an imbalance of antioxidant systems, which can be linked to AD pathophysiology. Objective: Verify the difference between the activity of antioxidant enzymes and products of the oxidation process in peripheral blood in non-trisomic (NT) and trisomic (DS) adults and elders and respective associations with cognitive impairment. Methods: A total of 120 subjects were included in this study. Sociodemographic and clinical information were collected as per protocol for participants in DS and NT groups. The cognitive state of the DS participants was established according to the Brazilian version of the Cambridge Examination for Mental Disorders of Older People with Down's syndrome and Others with Intellectual Disabilities (CAMDEX-DS). The CAMDEX interview was used for this purpose for participants in the NT group. Plasma samples were collected to evaluate protein carbonyl content, superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), malondialdehyde (MDA), and 4-hydroxy-2-nonenal (HNE). Results: We found increased levels of SOD and CAT activity in the DS group. When the groups were stratified by cognitive decline, elevated levels of SOD and CAT activity were found both in DS groups with and without decline. The activity of GPx was similar between the groups, as well as MDA and HNE. Conclusion: The results suggest that alterations of the antioxidative processes can be implicated in the onset of neurodegeneration observed in individuals with DS.
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e090340
Lithium as a pharmacological approach to treat behavioral complications in Alzheimer’s disease: a preclinical study
Background: Nearly all individuals with Alzheimer’s disease (AD) develop neuropsychiatric symptoms (NPS). Lithium is a mood‐stabilizer and is efficient in reducing disruptive behaviors in bipolar‐disorder; this characteristic could be an opportunity to investigate the use of lithium in treating behavioral changes in AD.Method: We tested lithium carbonate treatment in 3xTg‐AD and age‐matched Wild‐type male mice (CEUA/PROCESS: 1605/2020; 4127240122). The drug was administered ad libitum via lithium‐supplemented chow (1.0g Li2CO3/kg of chow; 12‐weeks) from 9‐ to 12‐month‐old. Two behavioral test batteries were performed: (1) open‐field test (OFT), novel‐object recognition test (NORT), elevated zero‐maze test (EZMT), and rotarod test; (2) tail‐suspension test (TST), forced‐swim test (FST), and sucrose preference test (SPT). Immunohistochemistry method was performed to analyze amyloid‐β (Aβ) accumulation (6E10) in areas of the brain. Statistical analysis was performed using two‐way ANOVA followed by Bonferroni post‐hoc test and unpaired t‐test (IBM_SPSS Statistics® software 23). We considered statistically significant p(1, 28) = 37.15; p(1, 28) = 19.44; p(1, 28) = 11.70; p(1, 28) = 7.96; p(1, 24) = 17.86; p(1, 28) = 8.37; p(1, 28) = 7.99; p(1, 21) = 571.90; p(1, 20) = 357.28; p(1, 20) = 417.74; p(1, 20) = 7073.19; p(1, 21) = 1562.86; p(1, 22) = 419.79; p<0.001), in 3xTg‐AD+Lithium mice versus 3xtg‐AD; suggesting the neuroprotective action of lithium, which partially explains the positive cognitive and non‐cognitive behavioral changes observed with chronic lithium treatment.Conclusion: The efficacy of a low‐dose lithium treatment in improving cognitive loss and NPS suggest it as therapeutic potential to treat AD.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S1) , e090340
Open AccessLithium as a pharmacological approach to treat behavioral complications in Alzheimer’s disease: a preclinical study
Background: Nearly all individuals with Alzheimer’s disease (AD) develop neuropsychiatric symptoms (NPS). Lithium is a mood‐stabilizer and is efficient in reducing disruptive behaviors in bipolar‐disorder; this characteristic could be an opportunity to investigate the use of lithium in treating behavioral changes in AD.Method: We tested lithium carbonate treatment in 3xTg‐AD and age‐matched Wild‐type male mice (CEUA/PROCESS: 1605/2020; 4127240122). The drug was administered ad libitum via lithium‐supplemented chow (1.0g Li2CO3/kg of chow; 12‐weeks) from 9‐ to 12‐month‐old. Two behavioral test batteries were performed: (1) open‐field test (OFT), novel‐object recognition test (NORT), elevated zero‐maze test (EZMT), and rotarod test; (2) tail‐suspension test (TST), forced‐swim test (FST), and sucrose preference test (SPT). Immunohistochemistry method was performed to analyze amyloid‐β (Aβ) accumulation (6E10) in areas of the brain. Statistical analysis was performed using two‐way ANOVA followed by Bonferroni post‐hoc test and unpaired t‐test (IBM_SPSS Statistics® software 23). We considered statistically significant p(1, 28) = 37.15; p(1, 28) = 19.44; p(1, 28) = 11.70; p(1, 28) = 7.96; p(1, 24) = 17.86; p(1, 28) = 8.37; p(1, 28) = 7.99; p(1, 21) = 571.90; p(1, 20) = 357.28; p(1, 20) = 417.74; p(1, 20) = 7073.19; p(1, 21) = 1562.86; p(1, 22) = 419.79; p<0.001), in 3xTg‐AD+Lithium mice versus 3xtg‐AD; suggesting the neuroprotective action of lithium, which partially explains the positive cognitive and non‐cognitive behavioral changes observed with chronic lithium treatment.Conclusion: The efficacy of a low‐dose lithium treatment in improving cognitive loss and NPS suggest it as therapeutic potential to treat AD.
- 1 September 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (9) , 2935-2944
Lithium and Stroke Recovery: A Systematic Review and Meta-Analysis of Stroke Models in Rodents and Human Data
Background: Lithium has neuroprotective effects in animal models of stroke, but benefits in humans remain uncertain. This article aims to systematically review the available evidence of the neuroprotective and regenerative effects of lithium in animal models of stroke, as well as in observational and trial stroke studies in humans. Methods: This systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched Medline, Embase, and PsycINFO for preclinical and clinical studies published between January 2000 and September 2021. A random-effects meta-analysis was conducted from observational studies. Results: From 1625 retrieved studies, 42 were included in the systematic review. Of those, we identified 36 rodent models of stroke using preinsult or postinsult treatment with lithium, and 6 studies were conducted in human samples, of which 4 could be meta-analyzed. The review of animal models was stratified according to the type of stroke and outcomes. Human data were subdivided into observational and intervention studies. Treatment of rodents with lithium was associated with smaller stroke volumes, decreased apoptosis, and improved poststroke function. In humans, exposure to lithium was associated with a lower risk of stroke among adults with bipolar disorder in 2 of 4 studies. Two small trials showed equivocal clinical benefits of lithium poststroke. Conclusions: Animal models of stroke show consistent biological and functional evidence of benefits associated with lithium treatment, whereas human evidence remains sparse and inconclusive. The potential role of lithium in poststroke recovery is yet to be adequately tested in humans.
- 1 September 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (9) , 2935-2944
Lithium and Stroke Recovery: A Systematic Review and Meta-Analysis of Stroke Models in Rodents and Human Data
Background: Lithium has neuroprotective effects in animal models of stroke, but benefits in humans remain uncertain. This article aims to systematically review the available evidence of the neuroprotective and regenerative effects of lithium in animal models of stroke, as well as in observational and trial stroke studies in humans. Methods: This systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched Medline, Embase, and PsycINFO for preclinical and clinical studies published between January 2000 and September 2021. A random-effects meta-analysis was conducted from observational studies. Results: From 1625 retrieved studies, 42 were included in the systematic review. Of those, we identified 36 rodent models of stroke using preinsult or postinsult treatment with lithium, and 6 studies were conducted in human samples, of which 4 could be meta-analyzed. The review of animal models was stratified according to the type of stroke and outcomes. Human data were subdivided into observational and intervention studies. Treatment of rodents with lithium was associated with smaller stroke volumes, decreased apoptosis, and improved poststroke function. In humans, exposure to lithium was associated with a lower risk of stroke among adults with bipolar disorder in 2 of 4 studies. Two small trials showed equivocal clinical benefits of lithium poststroke. Conclusions: Animal models of stroke show consistent biological and functional evidence of benefits associated with lithium treatment, whereas human evidence remains sparse and inconclusive. The potential role of lithium in poststroke recovery is yet to be adequately tested in humans.
- 8 January 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (3) , 1543-1559
Inhibition of TRPM2 by AG490 Is Neuroprotective in a Parkinson’s Disease Animal Model
Parkinson’s disease (PD) is characterized by motor impairment and dopaminergic neuronal loss. There is no cure for the disease, and treatments have several limitations. The transient receptor potential melastatin 2 (TRPM2), a calcium-permeable non-selective cation channel, has been reported to be upregulated in neuronal death. However, there are no in vivo studies evaluating TRPM2’s role and neuroprotective effects in PD. Here, we test the hypothesis that TRPM2 is upregulated in the 6-hydroxydopamine (6-OHDA) mouse model of PD and that its inhibition, by the AG490, is neuroprotective. For that, AG490 or vehicle were intraperitoneally administered into C57BL/6 mice. Mice then received 6-OHDA into the right striatum. Motor behavior assessments were evaluated 6, 13, and 20 days after surgery using the cylinder and apomorphine-induced rotational testes, and 7, 14, and 21 days after surgery using rotarod test. Brain samples of substantia nigra (SNc) and striatum (CPu) were collected for immunohistochemistry and immunoblotting on days 7 and 21. We showed that TRPM2 protein expression was upregulated in 6-OHDA-treated animals. In addition, AG490 prevented dopaminergic neuron loss, microglial activation, and astrocyte reactivity in 6-OHDA-treated animals. The compound improved motor behaviors and Akt/GSK-3β/caspase-3 signaling. We conclude that TRPM2 inhibition by AG490 is neuroprotective in the 6-OHDA model and that the TRPM2 channel may represent a potential therapeutic target for PD.
- 8 January 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (3) , 1543-1559
Inhibition of TRPM2 by AG490 Is Neuroprotective in a Parkinson’s Disease Animal Model
Parkinson’s disease (PD) is characterized by motor impairment and dopaminergic neuronal loss. There is no cure for the disease, and treatments have several limitations. The transient receptor potential melastatin 2 (TRPM2), a calcium-permeable non-selective cation channel, has been reported to be upregulated in neuronal death. However, there are no in vivo studies evaluating TRPM2’s role and neuroprotective effects in PD. Here, we test the hypothesis that TRPM2 is upregulated in the 6-hydroxydopamine (6-OHDA) mouse model of PD and that its inhibition, by the AG490, is neuroprotective. For that, AG490 or vehicle were intraperitoneally administered into C57BL/6 mice. Mice then received 6-OHDA into the right striatum. Motor behavior assessments were evaluated 6, 13, and 20 days after surgery using the cylinder and apomorphine-induced rotational testes, and 7, 14, and 21 days after surgery using rotarod test. Brain samples of substantia nigra (SNc) and striatum (CPu) were collected for immunohistochemistry and immunoblotting on days 7 and 21. We showed that TRPM2 protein expression was upregulated in 6-OHDA-treated animals. In addition, AG490 prevented dopaminergic neuron loss, microglial activation, and astrocyte reactivity in 6-OHDA-treated animals. The compound improved motor behaviors and Akt/GSK-3β/caspase-3 signaling. We conclude that TRPM2 inhibition by AG490 is neuroprotective in the 6-OHDA model and that the TRPM2 channel may represent a potential therapeutic target for PD.
- 1 August 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 760, 136078
Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
- 1 August 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 760, 136078
Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
- 1 November 2020
- Published by Elsevier in Experimental Gerontology
- Vol. 141, 111097
Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration
- 1 November 2020
- Published by Elsevier in Experimental Gerontology
- Vol. 141, 111097
Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration
- 1 June 2020
- Published by Elsevier in Behavioural Brain Research
- Vol. 387, 112607
Physical exercise protects against mitochondria alterations in the 6-hidroxydopamine rat model of Parkinson’s disease
- 1 June 2020
- Published by Elsevier in Behavioural Brain Research
- Vol. 387, 112607
Physical exercise protects against mitochondria alterations in the 6-hidroxydopamine rat model of Parkinson’s disease